Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
American Society of Hematology (ASH) 2026 guidelines on diagnosis of light chain/AL amyloidosis emphasizing serum and urine immunofixation, serum free light chains, and surrogate biopsies (both bone marrow and fat pad)․”
Title: American Society of Hematology (ASH) 2026 Guidelines on Diagnosis of Light Chain Amyloidosis
Authors: Vishal Kukreti, Matthew D Seftel, Maria Adela Aguirre, Muayad Azzam, Deborah Boedicker, Naresh Bumma, Antonia S. Carroll, Raymond Comenzo, Joselle Cook, Noel R Dasgupta, Alfredo De La Torre, Angela Dispenzieri, Faizi Jamal, Hassan Kawtharany, Jack Khouri, Nelson Leung, Jamil Nazzal, Maria M Picken, Shahzad Raza, Vaishali Sanchorawala, Nitasha Sarswat, Hira Shaikh, Daulath Singh, and Reem A. Mustafa.
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
